Anticoagulation Regimes in COVID-19 Patients

Local trial investigators entered data in the COVID STEROID 2 database using web-based case report files, including data regarding baseline characteristics, mortality and allocation. Data on TE and bleeding, laboratory coagulation parameters, and data on anticoagulation regime were retrieved from local databases. Both in Denmark and Sweden, these local databases were built by reviewing patient data in electronic health records (EHR). This was done by medical students, physicians, and research nurses. If the EHR was difficult to interpret, the reviewer was instructed to discuss with the responsible investigator (i.e., an experienced senior physician) at the site. Regimes of anticoagulation were categorized as follows: low dose of low-molecular-weight heparin (LMWH): 2500–4500 IU daily for tinzaparin, 2500–5000 IU daily for dalteparin or ≤ 40 mg daily for enoxaparin; intermediate dose of LMWH: > 4500 IU but < 175 IU/kg of body weight daily for tinzaparin, > 5000 IU but < 200 IU/kg of body weight daily for dalteparin, or > 40 mg but < 1 mg/kg of body weight daily for enoxaparin; and high dose of LMWH: ≥ 175 IU/kg of body weight daily for tinzaparin, ≥ 200 IU/kg of body weight daily for dalteparin, or ≥ 1 mg/kg of body weight daily of enoxaparin.